Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2014 1
2015 1
2016 1
2017 2
2018 1
2020 1
2021 2
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Ca(2+) release-activated Ca(2+) channel inhibitors.
Pevarello P, Cainarca S, Liberati C, Tarroni P, Piscitelli F, Severi E. Pevarello P, et al. Among authors: liberati c. Pharm Pat Anal. 2014 Mar;3(2):171-82. doi: 10.4155/ppa.14.7. Pharm Pat Anal. 2014. PMID: 24588594 Review.
FFA4/GPR120 agonists: a survey of the recent patent literature.
Formicola R, Pevarello P, Kuhn C, Liberati C, Piscitelli F, Sodano M. Formicola R, et al. Among authors: liberati c. Pharm Pat Anal. 2015;4(6):443-51. doi: 10.4155/ppa.15.33. Pharm Pat Anal. 2015. PMID: 26580993 Review.
A potassium channel agonist protects hearing function and promotes outer hair cell survival in a mouse model for age-related hearing loss.
Peixoto Pinheiro B, Müller M, Bös M, Guezguez J, Burnet M, Tornincasa M, Rizzetto R, Rolland JF, Liberati C, Lohmer S, Adel Y, Löwenheim H. Peixoto Pinheiro B, et al. Among authors: liberati c. Cell Death Dis. 2022 Jul 11;13(7):595. doi: 10.1038/s41419-022-04915-5. Cell Death Dis. 2022. PMID: 35817766 Free PMC article.
The atypical receptor CCRL2 is required for CXCR2-dependent neutrophil recruitment and tissue damage.
Del Prete A, Martínez-Muñoz L, Mazzon C, Toffali L, Sozio F, Za L, Bosisio D, Gazzurelli L, Salvi V, Tiberio L, Liberati C, Scanziani E, Vecchi A, Laudanna C, Mellado M, Mantovani A, Sozzani S. Del Prete A, et al. Among authors: liberati c. Blood. 2017 Sep 7;130(10):1223-1234. doi: 10.1182/blood-2017-04-777680. Epub 2017 Jul 25. Blood. 2017. PMID: 28743719 Free article.
Novel selective, potent naphthyl TRPM8 antagonists identified through a combined ligand- and structure-based virtual screening approach.
Beccari AR, Gemei M, Lo Monte M, Menegatti N, Fanton M, Pedretti A, Bovolenta S, Nucci C, Molteni A, Rossignoli A, Brandolini L, Taddei A, Za L, Liberati C, Vistoli G. Beccari AR, et al. Among authors: liberati c. Sci Rep. 2017 Sep 8;7(1):10999. doi: 10.1038/s41598-017-11194-0. Sci Rep. 2017. PMID: 28887460 Free PMC article.
Publisher Correction: Novel selective, potent naphthyl TRPM8 antagonists identified through a combined ligand- and structure-based virtual screening approach.
Beccari AR, Gemei M, Lo Monte M, Menegatti N, Fanton M, Pedretti A, Bovolenta S, Nucci C, Molteni A, Rossignoli A, Brandolini L, Taddei A, Za L, Liberati C, Vistoli G. Beccari AR, et al. Among authors: liberati c. Sci Rep. 2018 Mar 6;8(1):4250. doi: 10.1038/s41598-018-21902-z. Sci Rep. 2018. PMID: 29511237 Free PMC article.
Binding Mode Exploration of B1 Receptor Antagonists' by the Use of Molecular Dynamics and Docking Simulation-How Different Target Engagement Can Determine Different Biological Effects.
Gemei M, Talarico C, Brandolini L, Manelfi C, Za L, Bovolenta S, Liberati C, Vecchio LD, Russo R, Cerchia C, Allegretti M, Beccari AR. Gemei M, et al. Among authors: liberati c. Int J Mol Sci. 2020 Oct 16;21(20):7677. doi: 10.3390/ijms21207677. Int J Mol Sci. 2020. PMID: 33081372 Free PMC article.
12 results